ClinicalTrials.gg
RecruitingNCT07709897Updated Aug 26, 2026

A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting

A Phase 2 interventional study of HRS5580 for injection combined with palonosetron hydrochloride; and HRS5580 for injection combined with palonosetron hydrochloride in Prevention of Postoperative Nausea and Vomiting, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for injection combined with palonosetron hydrochloride for the prevention of postoperative nausea and vomiting.

02

Conditions studied

  • Prevention of Postoperative Nausea and Vomiting

Browse trials for

03

In context

Vomiting

793 studies on the registry are indexed under Vomiting; 99 are open to participants now.

This study's planned enrollment of 260 is above the median of 103 across 673 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form prior to the start of any trial-related activities, fully understand the purpose and significance of the study, and voluntarily comply with the trial procedures;
  2. 2、Scheduled to undergo elective surgery under general anesthesia with an expected surgical duration of ≥ 2 hours (surgery types include gynecological surgery, hepatobiliary surgery, intestinal surgery, urological surgery, etc.);
  3. Aged ≥ 18 years;
  4. (BMI) between 18 kg/m² and 28 kg/m² (inclusive);
  5. (ASA) Physical Status Classification I or II;
  6. Expected postoperative hospital stay ≥ 72 hours;
  7. Presence of ≥ 3 risk factors for PONV (female, history of PONV or motion sickness, non-smoker, postoperative opioid use);
  8. Female participants of must have a negative serum pregnancy test within 7 days prior to randomization and must not be breastfeeding; female participants of childbearing potential must use highly effective measures (see Appendix 13.1.2) from 30 days prior to the screening period until 6 months after the last dose, and have no plans for egg donation or pregnancy; male participants with a female partner of childbearing potential must use highly effective contraceptive measures from the time of signing the informed consent form until 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of vestibular disorders (including but not limited to: peripheral vestibular syndrome, central vestibular syndrome, etc.) or dizziness (excluding history of motion sickness), or a history of central nervous system disorders that may cause nausea and vomiting;
  2. History of chronic nausea or vomiting/retching;
  3. History of new-onset myocardial infarction or unstable angina pectoris within 6 months prior to screening, or history of severe cardiac arrhythmias such as second-degree or higher atrioventricular block, or history of (NYHA) Functional Classification Class II or higher;
  4. Any other medical condition that, in the investigator's judgment, may confound the assessment of postoperative nausea and/or vomiting.
  5. Random blood glucose > 11.1 mmol/L during the screening period;
  6. Prolonged during the screening period: > 450 ms in males, > 470 ms in females;
  7. Systolic blood pressure ≥ 160 mmHg or \< 90 mmHg, and/or diastolic blood pressure ≥ 100 mmHg or \< 60 mmHg from the time of signing the ICF to before entering the operating room, which is considered by the investigator;
  8. Abnormal liver function during the screening period: (AST) and/or alanine aminotransferase (ALT) and/or gamma-glutamyl transferase (GGT) ≥ 3.0 × and/or total (TBIL) ≥ 1.5 × ULN;
  9. Abnormal renal function during the screening period: serum creatinine (Cr) ≥ 1.5 × ULN and/or participants undergoing dialysis;
  10. Positive test for surface antigen (HBsAg), antibody (HCVAb), syphilis antibody, or (HIV) antibody during the screening period;
  11. Known allergy or to NK-1 receptor antagonists and/or 5-HT3 receptor antagonists and other medications that may be used during the trial;
  12. Receipt of any treatment with potential antiemetic effects, including pharmacological and non-pharmacological treatments, within 48 hours prior to the start of product administration (refer to the Prohibited Concomitant Treatments table);
  13. Participants whose last use of an opioid occurred less than 5 half-lives before the start of investigational product administration;
  14. Use of strong inducers, strong inhibitors, or specific CYP2D6 substrates within 28 days prior to randomization.
  15. Participants who have received chemotherapy within 4 weeks prior to surgery;
  16. Use of other medications that may affect antiemetic efficacy as determined by the investigator, with the last use occurring less than 5 half-lives before the start of investigational product administration (based on the actual drug label; if the half-life is unknown, a 48-hour should be applied).
  17. Participants scheduled to receive anesthetic methods not specified in the protocol, including local anesthesia, regional anesthesia [e.g., nerve block, neuraxial block (including subarachnoid block, epidural anesthesia, or combined spinal-epidural anesthesia)], and total intravenous anesthesia;
  18. Participants expected to require an in-place nasogastric tube or orogastric tube after surgery completion;
  19. Participants expected to be transferred to the ICU for sedation with endotracheal intubation after surgery or those unable to undergo nausea and vomiting record assessments;
  20. Participation in another clinical study of a drug or device within 3 months prior to screening (having signed and received investigational product/device treatment);
  21. Daily excessive consumption of tea, coffee, grapefruit/grapefruit juice, pomelo juice, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 14 days prior to randomization;
  22. Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS5580 for injection combined with palonosetron hydrochloride

    Drug: HRS5580 for injection combined with palonosetron hydrochloride;

  • Experimental
    Treatment group B: HRS5580 for injection combined with palonosetron hydrochloride

    Drug: HRS5580 for injection combined with palonosetron hydrochloride

  • Placebo comparator
    Treatment group C

    Drug: HRS5580 for injection blank preparation combined with palonosetron hydrochloride

Interventions

  • DrugHRS5580 for injection combined with palonosetron hydrochloride;

    Drug page: Palonosetron

    HRS5580 for injection combined with palonosetron hydrochloride; low dose

  • DrugHRS5580 for injection combined with palonosetron hydrochloride

    Drug page: Palonosetron

    HRS5580 for injection combined with palonosetron hydrochloride; high dose

  • DrugHRS5580 for injection blank preparation combined with palonosetron hydrochloride

    HRS5580 for injection blank preparation combined with palonosetron hydrochloride

06

What researchers measure

Primary outcomes

  1. Complete response rate within 72 hours after extubation (defined as the proportion of participants with no vomiting and no use of rescue therapy)

    Time frame: within 72 hours after extubation

Secondary outcomes

  1. Complete response rate within 24hours, 48hours, 24-48hours, 24-72hours, 96hours, and 120hours after extubation

    Time frame: within 24hours, 48hours, 24-48hours, 24-72hours, 96hours, and 120hours after extubation

  2. Vomiting-free rate within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

    Time frame: within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

  3. Nausea-free rate within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

    Time frame: within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

  4. PONV (postoperative nausea and vomiting)rate within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

    Time frame: within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

  5. Proportion of participants without significant nausea within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

    Time frame: within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

  6. Nausea severity score within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation (assessed based on the worst nausea severity during each time interval)

    Time frame: within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation (assessed based on the worst nausea severity during each time interval)

  7. Proportion of participants without rescue therapy within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

    Time frame: without rescue therapy within 24hours, 48hours, 24-48hours, 72hours, 24-72hours, 96hours, and 120hours after extubation

  8. Time to first vomiting after extubation

    Time frame: Post-extubation 0-120 hours

  9. Time to first significant nausea after extubation

    Time frame: Post-extubation 0-120 hours

  10. Time to first rescue therapy after extubation

    Time frame: Post-extubation 0-120 hours

  11. Investigator satisfaction score at 120 hours after extubation

    Time frame: Investigator satisfaction score at 120 hours after extubation

07

Study locations

2 of 2 sites recruiting
  • Fudan University Zhongshan Hospital
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Changhong Miao · Principal investigator
  • Tianjin Nankai Hospital
    Tianjin, Tianjin Municipality 300100, China
    Recruiting
    • Jianbo Yu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07709897
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Aug 6, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Lei Tang
Contact
lei.tang.lt31@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palonosetron

Start the discussion